Head-To-Head Analysis: Sophiris Bio (SPHS) versus Allergan PLC. (AGN)
Sophiris Bio (NASDAQ: SPHS) and Allergan PLC. (NYSE:AGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.
Institutional and Insider Ownership
5.5% of Sophiris Bio shares are owned by institutional investors. Comparatively, 84.8% of Allergan PLC. shares are owned by institutional investors. 3.9% of Sophiris Bio shares are owned by insiders. Comparatively, 0.4% of Allergan PLC. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Sophiris Bio and Allergan PLC.’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Sophiris Bio||N/A||N/A||-$10.78 million||($0.26)||-7.15|
|Allergan PLC.||$15.07 billion||5.19||$6.00 billion||$28.15||8.27|
Allergan PLC. has higher revenue and earnings than Sophiris Bio. Sophiris Bio is trading at a lower price-to-earnings ratio than Allergan PLC., indicating that it is currently the more affordable of the two stocks.
Allergan PLC. pays an annual dividend of $2.80 per share and has a dividend yield of 1.2%. Sophiris Bio does not pay a dividend. Allergan PLC. pays out 9.9% of its earnings in the form of a dividend.
Volatility and Risk
Sophiris Bio has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Allergan PLC. has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Sophiris Bio and Allergan PLC., as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sophiris Bio presently has a consensus price target of $6.60, indicating a potential upside of 254.84%. Allergan PLC. has a consensus price target of $276.59, indicating a potential upside of 18.77%. Given Sophiris Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Sophiris Bio is more favorable than Allergan PLC..
This table compares Sophiris Bio and Allergan PLC.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Allergan PLC. beats Sophiris Bio on 9 of the 14 factors compared between the two stocks.
About Sophiris Bio
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.
About Allergan PLC.
Allergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.